Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amplify Cybersecurity ETF (HACK) vs Tango Therapeutics Inc. (TNGX) Price & Performance

Amplify Cybersecurity ETFTrade
Tango Therapeutics Inc.Trade

Price performance (Past 24H)

Key statistics

Amplify Cybersecurity ETF vs Tango Therapeutics Inc. — how do they compare? Amplify Cybersecurity ETF trades at $122 (market cap $3.56B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Amplify Cybersecurity ETF and Tango Therapeutics Inc. are close in size by market cap, and Amplify Cybersecurity ETF is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Amplify Cybersecurity ETF for 27 Days and Tango Therapeutics Inc. for 0 Days on average.

HACKTNGX
Market Cap
$3.56B$3.75B
Volume
331,1979,619,106
Sector
Sector/ThematicHealth
52-Week High
$130.76$32.90
52-Week Low
$70.69$7.50
Typical Hold Time
27 Days0 Days
Enterprise Value
—$2.77B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amplify Cybersecurity ETF

HACK trades at $127.09, down 0.12% on the day, but maintains a bullish technical stance with moving averages signaling strength and momentum indicators like ADX showing strong trend confirmation. The ETF recently hit a 52-week high, driven by AI safety concerns and rising cybersecurity demand, though short interest has surged significantly, indicating mixed sentiment. Financial ratios are not applicable as this is an ETF tracking a basket of cybersecurity stocks.

The outlook for HACK is supported by structural growth in cybersecurity spending, particularly from AI-driven threats, but faces risks from elevated short interest and potential sector rotation. Upside depends on continued sector outperformance, while downside risks include profit-taking after strong gains and broader tech volatility.

Tango Therapeutics Inc.

TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.

Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HACK
100% Buy0% Sell
Avg holding period · 27 Days
TNGX
100% Buy0% Sell
Avg holding period · 0 Days

About Amplify Cybersecurity ETF

HACK provides diversified exposure to the global cybersecurity industry. It invests across the full value chain, including hardware, software, and consulting services, with key holdings in firms like Broadcom, Cisco, and Palo Alto Networks.

Read more on HACK →

About Tango Therapeutics Inc.

Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.

Read more on TNGX →